Sie sind bereits eingeloggt. Klicken Sie auf 2. tolino select Abo, um fortzufahren.
Bitte loggen Sie sich zunächst in Ihr Kundenkonto ein oder registrieren Sie sich bei bücher.de, um das eBook-Abo tolino select nutzen zu können.
Bladder Cancer: Diagnosis and Clinical Management is a 100% clinically-focused guide to bladder cancer, providing practical, modern and evidence-based guidance to the latest in diagnosis and management of the condition. It differs from other books in its complete clinical focus as opposed to a heavy analysis of pathogenesis or basic science. As a result, practicing urologists and oncologists in the clinical setting will find it an essential resource to consult. In addition to the latest in diagnostic tools and imaging methods, core focus is on the management of each form of cancer at its…mehr
Bladder Cancer: Diagnosis and Clinical Management is a 100% clinically-focused guide to bladder cancer, providing practical, modern and evidence-based guidance to the latest in diagnosis and management of the condition. It differs from other books in its complete clinical focus as opposed to a heavy analysis of pathogenesis or basic science. As a result, practicing urologists and oncologists in the clinical setting will find it an essential resource to consult. In addition to the latest in diagnostic tools and imaging methods, core focus is on the management of each form of cancer at its various stages with up to date genomic data and targeted therapies. Both drug therapies and the range of surgical options are covered, ensuring that this is the perfect tool for clinicians to consult when considering which type of management program is appropriate for each individual patient. A key addition is the final section dedicated to optimizing health care delivery, featuring chapters on highly topical issues such as quality of life, patient advocacy and surgical education. Full color throughout, and packed with excellent images, each chapter contains concise and didactic practical tips and tricks to enrich the reading experience, in addition to management algorithms and the very latest guidelines from the ASCO, AUA, ESMO and EAU concerning clinical management of bladder cancer.
Dieser Download kann aus rechtlichen Gründen nur mit Rechnungsadresse in A, B, BG, CY, CZ, D, DK, EW, E, FIN, F, GR, HR, H, IRL, I, LT, L, LR, M, NL, PL, P, R, S, SLO, SK ausgeliefert werden.
Die Herstellerinformationen sind derzeit nicht verfügbar.
Autorenporträt
Seth P. Lerner, Professor of Urology and Beth and Dave Swalm Chair in Urologic Oncology, Baylor College of Medicine, Houston, TX, USA Mark P. Schoenberg, MD, Professor and University Chair, The Department of Urology, The Montefiore Medical Center & The Albert Einstein College of Medicine, Bronx, NY USA Cora N. Sternberg, Chief, Department of Medical Oncology, San Camillo Forlanini Hospital, Rome, Italy and Adjunct Professor at La Sapienza University in Rome.
Inhaltsangabe
List of contributors vii Preface xii Acknowledgments xiii Part I: Diagnosis and treatment of non-muscle-invasive bladder cancer 1 Pathology 3 Hikmat Al-Ahmadie and Donna E. Hansel 2 Risk stratification of high?]grade Ta CIS and T1 urothelial carcinoma of the bladder 18 Tobias Klatte, Fred Witjes, Gary Steinberg, and Shahrokh F. Shariat 3 Utility of urine biomarkers 26 Derya Tilki and Alexandre R. Zlotta 4 Novel endoscopic techniques for the detection of bladder cancer 39 Ayman Soubra, Joseph C. Liao, and Badrinath Konety 5 Transurethral resection of bladder tumors 51 Jen-Jane Liu and Mark P. Schoenberg 6 Intravesical chemotherapy 64 Levent N. Türkeri, M.Guillaume Wientjes, and Jessie L.S. Au 7 Intravesical immunotherapy 76 Nilay M. Gandhi, Laura A. Bertrand, Donald L. Lamm, and Michael A. O'Donnell 8 HGT1 bladder cancer: Diagnosis and treatment 89 J.M. Gaya, J. Palou, and Edward M. Messing 9 What to do when bacillus Calmette-Guérin fails 98 Massimiliano Spaliviero, Guido Dalbagni, and Matthew Nielsen Part II: T2-4 10 Selection and perioperative management of patients undergoing radical cystectomy and urinary reconstruction 111 Robert S. Svatek and Alon Z. Weizer 11 Radical cystectomy: Techniques and outcomes 127 Siamak Daneshmand and Seth P. Lerner 12 Cystectomy in the female patient 144 Ryan Werntz, Georgios Gakis, Theresa Koppie, and Arnulf Stenzl 13 Laparoscopic/robotic radical cystectomy and urinary diversion: Outcomes 156 Kristina Wittig, Kevin Chan, Mark Kawachi, and Timothy G. Wilson 14 Robotic assisted radical cystectomy and urinary diversion: Clinical trials 167 George J.S. Kallingal, Angela B. Smith, Raj S. Pruthi, and Dipen J. Parekh 15 Role of extended lymphadenectomy 176 Eugene K. Cha, George N. Thalmann, and Bernard H. Bochner 16 Management of the urethra in the cystectomy patient 184 Kamal S. Pohar and Norm D. Smith 17 The role of radical cystectomy in patients with unresectable or regionally metastatic urothelial carcinoma of the bladder 190 Scott Delacroix Jr, Nathan Lawrentschuk, and Ashish M. Kamat Part III: Primary bladder-sparing therapy 18 Radical transurethral resection 201 Eduardo Solsona and Harry W. Herr 19 Partial cystectomy 212 Ahmed Haddad, Yair Lotan, and Arthur I. Sagalowsky 20 Integrating chemotherapy and radiotherapy for bladder cancer 221 Lior Z. Braunstein, William U. Shipley, Nicholas D. James, Andrea B. Apolo, and Jason A. Efstathiou Part IV: Urinary tract reconstruction 21 Orthotopic neobladder 235 Eila C. Skinner 22 Continent cutaneous diversion 244 Andreas Neisius and Joachim W. Thüroff 23 Non?]continent urinary diversion 258 Michael Rink, Fredrik Liedberg, and Margit Fisch Part V: Treatment of regionally advanced and metastatic bladder cancer 24 Molecular determinants of chemotherapy response 273 Matthew I. Milowsky, Peter H. O'Donnell, Thomas W. Flaig, and Dan Theodorescu 25 Neoadjuvant chemotherapy in the treatment of muscle-invasive bladder cancer 284 David I. Quinn and Cora N. Sternberg 26 Adjuvant chemotherapy for invasive bladder cancer 295 André P. Fay, Jeffrey J. Leow, and Joaquim Bellmunt 27 Treatment of metastatic bladder cancer 304 Gopa Iyer, Fabio Calabró, and Dean F. Bajorin 28 Treatment of poor risk patients 320 Maria De Santis and Matthew D. Galsky Part VI: Genomics and the current status of urothelial cancer 29 Molecular events in muscle?]invasive bladder cancer development 329 Jonathan Rosenberg, William Y. Kim, Jaegil Kim, and David J. Kwiatkowski 30 Cancer stem cells and intrinsic subtypes in bladder cancer 342 Keith Syson Chan and David J. McConkey 31 Multi-targeted agents in the treatment of urothelial carcinoma 353 Noah M. Hahn, Colin P.N. Dinney, and Guru Sonpavde Part VII: Optimizing healthcare delivery 32 Patient navigation and cancer navigator programs 365 Scott M. Gilbert and Michael Porter 33 Impact of health services on compliance and outcomes 375 Heather Honoré Goltz, Marc A. Kowalkowski, G. John Chen, and David M. Latini 34 Quality of life and survivorship 384 Nihal E. Mohamed and Cheryl T. Lee 35 Bladder cancer: Healthcare delivery and third party payers 395 Seth A. Strope and John L. Gore 36 Bladder cancer patient advocacy: Creating partnerships to advance patient care research and clinical trials 402 Diane Zipursky Quale and Rick Bangs Index 409
List of contributors vii Preface xii Acknowledgments xiii Part I: Diagnosis and treatment of non-muscle-invasive bladder cancer 1 Pathology 3 Hikmat Al-Ahmadie and Donna E. Hansel 2 Risk stratification of high?]grade Ta CIS and T1 urothelial carcinoma of the bladder 18 Tobias Klatte, Fred Witjes, Gary Steinberg, and Shahrokh F. Shariat 3 Utility of urine biomarkers 26 Derya Tilki and Alexandre R. Zlotta 4 Novel endoscopic techniques for the detection of bladder cancer 39 Ayman Soubra, Joseph C. Liao, and Badrinath Konety 5 Transurethral resection of bladder tumors 51 Jen-Jane Liu and Mark P. Schoenberg 6 Intravesical chemotherapy 64 Levent N. Türkeri, M.Guillaume Wientjes, and Jessie L.S. Au 7 Intravesical immunotherapy 76 Nilay M. Gandhi, Laura A. Bertrand, Donald L. Lamm, and Michael A. O'Donnell 8 HGT1 bladder cancer: Diagnosis and treatment 89 J.M. Gaya, J. Palou, and Edward M. Messing 9 What to do when bacillus Calmette-Guérin fails 98 Massimiliano Spaliviero, Guido Dalbagni, and Matthew Nielsen Part II: T2-4 10 Selection and perioperative management of patients undergoing radical cystectomy and urinary reconstruction 111 Robert S. Svatek and Alon Z. Weizer 11 Radical cystectomy: Techniques and outcomes 127 Siamak Daneshmand and Seth P. Lerner 12 Cystectomy in the female patient 144 Ryan Werntz, Georgios Gakis, Theresa Koppie, and Arnulf Stenzl 13 Laparoscopic/robotic radical cystectomy and urinary diversion: Outcomes 156 Kristina Wittig, Kevin Chan, Mark Kawachi, and Timothy G. Wilson 14 Robotic assisted radical cystectomy and urinary diversion: Clinical trials 167 George J.S. Kallingal, Angela B. Smith, Raj S. Pruthi, and Dipen J. Parekh 15 Role of extended lymphadenectomy 176 Eugene K. Cha, George N. Thalmann, and Bernard H. Bochner 16 Management of the urethra in the cystectomy patient 184 Kamal S. Pohar and Norm D. Smith 17 The role of radical cystectomy in patients with unresectable or regionally metastatic urothelial carcinoma of the bladder 190 Scott Delacroix Jr, Nathan Lawrentschuk, and Ashish M. Kamat Part III: Primary bladder-sparing therapy 18 Radical transurethral resection 201 Eduardo Solsona and Harry W. Herr 19 Partial cystectomy 212 Ahmed Haddad, Yair Lotan, and Arthur I. Sagalowsky 20 Integrating chemotherapy and radiotherapy for bladder cancer 221 Lior Z. Braunstein, William U. Shipley, Nicholas D. James, Andrea B. Apolo, and Jason A. Efstathiou Part IV: Urinary tract reconstruction 21 Orthotopic neobladder 235 Eila C. Skinner 22 Continent cutaneous diversion 244 Andreas Neisius and Joachim W. Thüroff 23 Non?]continent urinary diversion 258 Michael Rink, Fredrik Liedberg, and Margit Fisch Part V: Treatment of regionally advanced and metastatic bladder cancer 24 Molecular determinants of chemotherapy response 273 Matthew I. Milowsky, Peter H. O'Donnell, Thomas W. Flaig, and Dan Theodorescu 25 Neoadjuvant chemotherapy in the treatment of muscle-invasive bladder cancer 284 David I. Quinn and Cora N. Sternberg 26 Adjuvant chemotherapy for invasive bladder cancer 295 André P. Fay, Jeffrey J. Leow, and Joaquim Bellmunt 27 Treatment of metastatic bladder cancer 304 Gopa Iyer, Fabio Calabró, and Dean F. Bajorin 28 Treatment of poor risk patients 320 Maria De Santis and Matthew D. Galsky Part VI: Genomics and the current status of urothelial cancer 29 Molecular events in muscle?]invasive bladder cancer development 329 Jonathan Rosenberg, William Y. Kim, Jaegil Kim, and David J. Kwiatkowski 30 Cancer stem cells and intrinsic subtypes in bladder cancer 342 Keith Syson Chan and David J. McConkey 31 Multi-targeted agents in the treatment of urothelial carcinoma 353 Noah M. Hahn, Colin P.N. Dinney, and Guru Sonpavde Part VII: Optimizing healthcare delivery 32 Patient navigation and cancer navigator programs 365 Scott M. Gilbert and Michael Porter 33 Impact of health services on compliance and outcomes 375 Heather Honoré Goltz, Marc A. Kowalkowski, G. John Chen, and David M. Latini 34 Quality of life and survivorship 384 Nihal E. Mohamed and Cheryl T. Lee 35 Bladder cancer: Healthcare delivery and third party payers 395 Seth A. Strope and John L. Gore 36 Bladder cancer patient advocacy: Creating partnerships to advance patient care research and clinical trials 402 Diane Zipursky Quale and Rick Bangs Index 409
Es gelten unsere Allgemeinen Geschäftsbedingungen: www.buecher.de/agb
Impressum
www.buecher.de ist ein Internetauftritt der buecher.de internetstores GmbH
Geschäftsführung: Monica Sawhney | Roland Kölbl | Günter Hilger
Sitz der Gesellschaft: Batheyer Straße 115 - 117, 58099 Hagen
Postanschrift: Bürgermeister-Wegele-Str. 12, 86167 Augsburg
Amtsgericht Hagen HRB 13257
Steuernummer: 321/5800/1497
USt-IdNr: DE450055826
